In addition, the York-based firm says Dr Stuart Best has joined the company as senior director of operations.
Dr Roblin joins the firm from Pfizer global r&d where he was most recently senior vice president r&d, research head and site director. His experience crosses therapeutic areas within the spectrum of small and large molecule r&d.
Dr Best was previously head of bioanalysis at Merck, Scotland. His career has been distinguished by his leadership in applying progressively sophisticated analytical technologies to this expanding and complex area of chemistry. Prior to Merck, Dr Best developed his reputation as an authority in the use of mass spectrometry in bioanalysis at Charles River (Inveresk).
Xceleron makes key appointments
Hires board member and senior director of operations
You may also like
Research & Development
Medicines Discovery Catapult announces collaboration with £15.9m project on next-gen human disease modelling
The Medical Research Council, Wellcome Trust and Innovate UK will work with MDC to develop advanced, specific and highly reproducible human-based in vitro models of disease, with the aim of making them widely available to researchers in academia and industry
Research & Development
Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells
Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies